BC patients with BRCA1 mRNA-low expression are more likely to respond to anthracycline-based therapy [20] and have improved overall survival despite a significant correlation between BRCA1 mRNA-low expression and high histological grade [21]. The gene discussed is BRCA1; the disease is breast cancer.